Related Experiment Videos
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications
María-Jesús Pérez-Pérez1, Eva-María Priego, Ana-Isabel Hernández
1Instituto de Química Médica (CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain. mjperez@iqm.csic.es
Mini Reviews in Medicinal Chemistry
|December 27, 2005
Summary
Novel inhibitors targeting Thymidine Phosphorylase (TPase), also known as platelet-derived endothelial cell growth factor (PD-ECGF), are explored. These inhibitors hold potential for antiviral, anticancer, and anti-metastasis therapies by modulating angiogenesis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Thymidine Phosphorylase (TPase) catalyzes the breakdown of deoxynucleosides and is crucial for tumor progression.
- TPase, also known as platelet-derived endothelial cell growth factor (PD-ECGF), promotes angiogenesis and metastasis.
- Nucleoside analogues processed by TPase have antiviral and anticancer applications.
Purpose of the Study:
- To review recent strategies for discovering novel TPase inhibitors.
- To discuss the therapeutic potential of these inhibitors in various diseases.
Main Methods:
- Literature review of recent research on TPase inhibitors.
- Analysis of studies focusing on TPase's role in angiogenesis and tumor biology.
Main Results:
- Several novel approaches for TPase inhibitor development have emerged.
- These inhibitors show promise in preclinical studies for cancer and viral infections.
Conclusions:
- Targeting TPase offers a promising therapeutic strategy for cancer and viral diseases.
- Further research into TPase inhibitors could lead to new treatments for angiogenesis-related disorders.